French decree confirms separate payment for ICDs and vascular implants:
This article was originally published in Clinica
The French health ministry has published a decree confirming that implantable defibrillators and vascular implants are to be paid for separately from the standard stay group (GHS) tariffs. This is the French equivalent of the diagnosis-related group scheme of charging for hospital treatment. The decree, dated July 29, was published in the Journal officiel on September 2 and contains a list of the codes that specify the precise implants covered by the ruling.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.